Fair Value of Financial Instruments - Schedule of Inputs and Valuation Methodologies Used (Details) - Level 3 $ in Millions	Sep. 30, 2022 USD ($)	Sep. 30, 2021
Contingent Consideration | Pelican Therapeutics, Inc. | Discount rate | Probability weighted income approach
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Consideration		0.0752
Revenue earn-out | Elusys Therapeutics | Discount rate | Discounted cash flow analysis
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Consideration	0.245
Revenue earn-out | Elusys Therapeutics | Future revenue projections | Discounted cash flow analysis
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Consideration	325.9
Contract deferred consideration | Elusys Therapeutics | Discount rate | Discounted cash flow analysis
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Consideration	0.15
Contract deferred consideration | Elusys Therapeutics | Future revenue projections | Discounted cash flow analysis
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Consideration	7.6
Minimum | Contingent Consideration | Pelican Therapeutics, Inc. | Probability of occurrence | Probability weighted income approach
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Consideration		0.049
Maximum | Contingent Consideration | Pelican Therapeutics, Inc. | Probability of occurrence | Probability weighted income approach
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Consideration		0.55